Allotera Therapeutics is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Allotera Therapeutics has raised $35.0M in total funding. The most recent round was Series C. The last funding was announced in July 2026.
Allotera Therapeutics's investors include Alpha Wave Global, Sands Capital Ventures, Intermediate Capital Group, Fidelity, Blood Cancer United, Inc..
Allotera Therapeutics is headquartered in St Louis, United States.
Allotera Therapeutics is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Allotera Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allotera Therapeutics — Funding & Investors." VCBacked, July 8, 2026, https://www.vcbacked.co/company/wugen. Accessed November 12, 2026.
VCBacked. (2026). Allotera Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/wugen
{{cite web |title=Allotera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/wugen |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Allotera Therapeutics? Request a listing update